Nothing Special   »   [go: up one dir, main page]

PT3049439T - Nanocorpos biespecíficos - Google Patents

Nanocorpos biespecíficos

Info

Publication number
PT3049439T
PT3049439T PT147770788T PT14777078T PT3049439T PT 3049439 T PT3049439 T PT 3049439T PT 147770788 T PT147770788 T PT 147770788T PT 14777078 T PT14777078 T PT 14777078T PT 3049439 T PT3049439 T PT 3049439T
Authority
PT
Portugal
Prior art keywords
bispecific nanobodies
nanobodies
bispecific
Prior art date
Application number
PT147770788T
Other languages
English (en)
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51627294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3049439(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of PT3049439T publication Critical patent/PT3049439T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT147770788T 2013-09-26 2014-09-26 Nanocorpos biespecíficos PT3049439T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361882877P 2013-09-26 2013-09-26

Publications (1)

Publication Number Publication Date
PT3049439T true PT3049439T (pt) 2020-03-31

Family

ID=51627294

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147770788T PT3049439T (pt) 2013-09-26 2014-09-26 Nanocorpos biespecíficos

Country Status (10)

Country Link
US (2) US20160251440A1 (pt)
EP (1) EP3049439B1 (pt)
JP (1) JP6721503B2 (pt)
CN (2) CN115160441A (pt)
AU (1) AU2014326674B2 (pt)
CA (1) CA2925061C (pt)
ES (1) ES2779123T3 (pt)
PL (1) PL3049439T3 (pt)
PT (1) PT3049439T (pt)
WO (1) WO2015044386A1 (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2814962T3 (es) 2013-02-20 2021-03-29 Novartis Ag Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
CN107108744B (zh) 2014-08-19 2020-09-25 诺华股份有限公司 抗cd123嵌合抗原受体(car)用于癌症治疗
CN107667113B (zh) * 2015-02-05 2022-05-03 埃博灵克斯股份有限公司 通过c端改造的半胱氨酸连接的纳米抗体二聚体
JP7163028B2 (ja) * 2015-05-13 2022-10-31 アブリンクス エン．ヴェー． Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
IL274151B (en) 2015-05-21 2022-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
CA2989321A1 (en) 2015-06-29 2017-01-05 Immunogen, Inc. Anti-cd123 antibodies and conjugates and derivatives thereof
EP3349795B1 (en) * 2015-09-17 2021-03-17 The Scripps Research Institute Dual variable domain immunoconjugates and uses thereof
UA121914C2 (uk) * 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Молекула, що зв'язує pd1 і lag3
JP6768800B2 (ja) 2015-11-18 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｔｌａ４結合性物質
CN109071639B (zh) * 2015-11-18 2022-07-08 默沙东公司 Pd1/ctla4结合剂
EP3932945A1 (en) 2015-11-27 2022-01-05 Ablynx NV Polypeptides inhibiting cd40l
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EA201892693A1 (ru) 2016-05-20 2019-04-30 Харпун Терапьютикс, Инк. Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3
SG11201810327XA (en) 2016-05-20 2018-12-28 Harpoon Therapeutics Inc Single domain serum albumin binding protein
CN117700549A (zh) * 2016-11-16 2024-03-15 埃博灵克斯股份有限公司 能够结合CD123和TCRα/β的T细胞募集多肽
WO2018094282A1 (en) * 2016-11-18 2018-05-24 The Regents Of The University Of California Engineered antibodies and uses thereof
CN110198955A (zh) 2016-11-23 2019-09-03 哈普恩治疗公司 前列腺特异性膜抗原结合蛋白质
KR20190087539A (ko) * 2016-11-23 2019-07-24 하푼 테라퓨틱스, 인크. Psma 표적화 삼중특이성 단백질 및 사용 방법
RU2658764C1 (ru) * 2016-12-19 2018-06-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Селективный бифункциональный препарат на основе фрагментов одноцепочечных антител верблюжьих, нацеленный на опухолевые рецепторы cd47/cd44, предназначенный для терапии злокачественных новообразований
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US20210260162A1 (en) * 2017-03-31 2021-08-26 The Board Of Trustees Of The Leland Stanford Junior University Synthekine compositions and methods of use
US20210115158A1 (en) * 2017-04-03 2021-04-22 Georgia Tech Research Corporation Synthetic Particle Antibody Compositions And Uses Thereof
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
BR112019023855B1 (pt) 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc Proteínas de ligação à mesotelina
AU2018277343A1 (en) 2017-06-02 2020-01-02 Ablynx N.V. Adamts binding immunoglobulins
CN111465612B (zh) 2017-10-13 2024-08-27 哈普恩治疗公司 B细胞成熟抗原结合蛋白
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
AU2018387829A1 (en) 2017-12-22 2020-05-07 Argenx Bvba Bispecific antigen binding construct
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
IL297931B1 (en) 2018-09-25 2024-11-01 Harpoon Therapeutics Inc DLL3 binding proteins and methods of use
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
JP2022521428A (ja) 2019-02-25 2022-04-07 ザ・ユニバーシティ・オブ・シカゴ 抗炎症剤に連結されたｅｃｍ親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物
CN113677705A (zh) * 2019-03-04 2021-11-19 南通壹宸生物医药科技有限公司 新型双特异性结合分子及其药物偶联物
CN110407943B (zh) * 2019-04-25 2021-03-30 华南农业大学 一种克百威农药的纳米抗体及其制备方法和应用
CN114040926A (zh) * 2019-05-04 2022-02-11 印希比股份有限公司 结合cd123的多肽及其用途
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
AU2020286523A1 (en) 2019-06-03 2022-02-03 The University Of Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants
US20210147525A1 (en) 2019-10-18 2021-05-20 The Regents Of The University Of California Methods and compositions for treating pathogenic blood vessel disorders
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
AU2021232625A1 (en) 2020-03-05 2022-09-29 Umc Utrecht Holding B.V. Membrane ubiquitin ligases to target protein degradation
CA3178265A1 (en) 2020-06-18 2021-12-23 Umc Utrecht Holding B.V. Screening method for effective target - e3 ligase combinations
US20230256111A1 (en) 2020-06-24 2023-08-17 Sapreme Technologies B.V. Combination comprising an adc or an aoc comprising a vhh, and a saponin or a ligand-saponin conjugate
MX2023000031A (es) 2020-06-24 2023-04-19 Sapreme Tech Bv Conjugado de un anticuerpo de dominio unico, una saponina y una molecula efectora, composicion farmaceutica que comprende el mismo, uso terapeutico de dicha composicion farmaceutica.
WO2021259507A1 (en) 2020-06-24 2021-12-30 Sapreme Technologies B.V. Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
US20230270872A1 (en) 2020-06-24 2023-08-31 Sapreme Technologies B.V. Conjugate of saponin and single-domain antibody, pharmaceutical composition comprising said conjugate, therapeutic use thereof
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
EP4192502A4 (en) 2020-08-05 2024-10-09 Synthekine Inc COMPOSITIONS AND METHODS RELATING TO IL27 RECEPTOR BINDING
US12018085B2 (en) 2020-08-05 2024-06-25 Synthekine, Inc. Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
EP4200339A2 (en) * 2020-08-05 2023-06-28 Synthekine, Inc. Compositions and methods related to receptor pairings
WO2022032042A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il12 receptor synthetic cytokines and methods of use
US20230357414A1 (en) * 2020-08-05 2023-11-09 Synthekine, Inc. Il12rb2 binding molecules and methods of use
US12077594B2 (en) 2020-08-05 2024-09-03 Synthekine, Inc. IL2RG binding molecules and methods of use
WO2022031929A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il12rb1-binding molecules and methods of use
WO2022031940A2 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il28ra binding molecules and methods of use
WO2022032023A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il23r binding molecules and methods of use
AU2021321525A1 (en) * 2020-08-05 2023-03-30 Synthekine, Inc. IL10 receptor binding molecules and methods of use
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
WO2022117569A1 (en) * 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2023121447A1 (en) 2021-12-22 2023-06-29 Sapreme Technologies B.V. Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
GB202210679D0 (en) * 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-12rb2
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024036333A2 (en) * 2022-08-12 2024-02-15 Epibiologics, Inc. Degradation of egfr using a bispecific binding agent
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
US20240368250A1 (en) 2023-02-17 2024-11-07 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249396B2 (en) * 2004-05-05 2011-10-20 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
FR2879605B1 (fr) * 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
KR20070114765A (ko) * 2005-02-23 2007-12-04 메리맥 파마슈티컬즈, 인크. 생물학적 활성을 조절하기 위한 이특이성 결합제
US20090252681A1 (en) * 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
JP2009511032A (ja) * 2005-10-11 2009-03-19 アブリンクス エン．ヴェー． Ｅｇｆｒおよびｉｇｆ−ｉｒに対するナノボディおよびポリペプチド
KR20080077261A (ko) * 2005-12-06 2008-08-21 도만티스 리미티드 Ｅｇｆｒ 및/또는 ｖｅｇｆ에 대해 결합 특이성이 있는리간드 및 그의 사용 방법
EP1963370A1 (en) * 2005-12-06 2008-09-03 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
EP2195342A1 (en) * 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
WO2009068625A2 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US10981998B2 (en) * 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
WO2010043650A2 (en) * 2008-10-14 2010-04-22 Ablynx Nv Amino acid sequences directed against cellular receptors for viruses and bacteria
EP2621953B1 (en) * 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US20150158934A1 (en) * 2011-09-09 2015-06-11 Ucl Business Plc Broadly neutralizing vhh against hiv-1
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species

Also Published As

Publication number Publication date
WO2015044386A1 (en) 2015-04-02
CA2925061C (en) 2023-02-14
JP2016538242A (ja) 2016-12-08
PL3049439T3 (pl) 2020-07-13
EP3049439B1 (en) 2019-12-25
AU2014326674A1 (en) 2016-04-28
ES2779123T3 (es) 2020-08-13
US20160251440A1 (en) 2016-09-01
CN115160441A (zh) 2022-10-11
CN105814082A (zh) 2016-07-27
AU2014326674B2 (en) 2020-03-12
US20220242958A1 (en) 2022-08-04
JP6721503B2 (ja) 2020-07-15
EP3049439A1 (en) 2016-08-03
CA2925061A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
IL269528A (en) Anti- FCRH5 antibodies
PT3049439T (pt) Nanocorpos biespecíficos
HK1222846A1 (zh) 取代的苄基吡唑
GB201311487D0 (en) Bispecific molecules
HK1221717A1 (zh) 取代的苄基吡唑
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
GB201322583D0 (en) Antibodies
HK1222852A1 (zh) 二氨基雜芳基取代的吡唑
HK1220142A1 (zh) 抗體
HRP20171890T1 (hr) Supstituirani imidazopiridazini
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
HK1223362A1 (zh) 取代的吡唑並吡啶胺
HK1220972A1 (zh) 取代的噻唑並嘧啶
IL246271A0 (en) Converted piperidinyl-tetrahydroquinolines
IL245488B (en) Anti- ccl17 antibodies
SG2013084207A (en) Aptamers
GB201322021D0 (en) Aptamers
GB201312340D0 (en) Aptamers
GB201318283D0 (en) Antibodies
GB201313075D0 (en) Lorry
HU4268U (en) Multi purposal glass-panel